Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2021 3
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Clinical application of stem cell therapy in neurogenic bladder: a systematic review and meta-analysis.
Salehi-Pourmehr H, Nouri O, Naseri A, Roshangar L, Rahbarghazi R, Sadigh-Eteghad S, Mahmoudi J, Mostafaei H, Roshandel MR, Hoseini L, Abolhasanpour N, Mostafaei A, Hajebrahimi S, Hashim H. Salehi-Pourmehr H, et al. Among authors: roshandel mr. Int Urogynecol J. 2022 Aug;33(8):2081-2097. doi: 10.1007/s00192-021-04986-6. Epub 2021 Nov 12. Int Urogynecol J. 2022. PMID: 34767058 Review.
Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy.
Fletcher SA, Pallauf M, Watts EK, Lombardo KA, Campbell JA, Rezaee ME, Rouprêt M, Boorjian SA, Potretzke AM, Roshandel MR, Ploussard G, Djaladat H, Ghoreifi A, Mari A, Campi R, Khene ZE, Raman JD, Kikuchi E, Rink M, Abdollah F, Boormans JL, Fujita K, D'Andrea D, Soria F, Breda A, Hoffman-Censits J, McConkey DJ, Shariat SF, Pradere B, Singla N. Fletcher SA, et al. Among authors: roshandel mr. Eur Urol Oncol. 2024 Jan 22:S2588-9311(24)00035-X. doi: 10.1016/j.euo.2024.01.010. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38262800
Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer.
Beksac AT, Ratnani P, Dovey Z, Parekh S, Falagario U, Roshandel R, Sobotka S, Kewlani D, Davis A, Weil R, Bashorun H, Jambor I, Lewis S, Haines K, Tewari AK. Beksac AT, et al. Among authors: roshandel r. Cancer Rep (Hoboken). 2022 Mar;5(3):e1492. doi: 10.1002/cnr2.1492. Epub 2021 Dec 20. Cancer Rep (Hoboken). 2022. PMID: 34931468 Free PMC article.